2010-11-09 12:35 IRW Consulting IRW offers 1 hour free consultation to your company within the areas clinical development and/or drug safety.

2009-03-12 14:55 Eisai AB Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma.